Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study.

ABSTRACT: The mammalian target of rapamycin plays an important role in multiple myeloma. The allosteric mammalian target of rapamycin inhibitor everolimus has long been approved for immunosuppression and has shown activity in certain cancers. This investigator-initiated phase I trial explored the use of everolimus in relapsed and/or refractory multiple myeloma patients who had received two or more lines of prior treatment. Following a dose-escalation design, it called for a fixed dose of oral everolimus. Blood drug levels were monitored and the biological activity of everolimus was evaluated in bone marrow. Seventeen patients were enrolled (age range, 52 to 76 years). All had been previously treated with stem cell transplantation and proteasome inhibitors and almost all with immunomodulatory drugs.

SUBMITTER: Gunther A 

PROVIDER: S-EPMC4380728 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature